Inspire Medical Systems Q1 2026 Earnings Call Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy INSP?
Source: seekingalpha
- Revenue Growth and Outlook Adjustment: Inspire Medical Systems reported a 1.6% year-over-year revenue increase to $204.6 million in Q1 2026, despite facing approximately $20 million in adverse impacts, leading management to revise the full-year revenue outlook to a range of $825 million to $875 million, reflecting a cautious stance on market conditions.
- Profitability Outlook Decline: The adjusted operating margin is now expected to range from 2% to 4%, with diluted EPS projected between $0.07 and $0.62, indicating challenges in navigating coding and reimbursement uncertainties that may affect future investor confidence.
- Cash Flow and Financial Health: The company generated $12.8 million in operating cash flow for the quarter and maintains a strong balance sheet with $400 million in cash and investments, demonstrating financial flexibility amid a challenging market environment.
- Coding and Reimbursement Challenges: Management highlighted that coding uncertainty has negatively impacted patient numbers, with anticipated adverse effects increasing to $40 million to $50 million in Q2, underscoring the importance of improving reimbursement processes in the coming months.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INSP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INSP
Wall Street analysts forecast INSP stock price to rise
19 Analyst Rating
13 Buy
6 Hold
0 Sell
Moderate Buy
Current: 56.700
Low
91.00
Averages
145.31
High
180.00
Current: 56.700
Low
91.00
Averages
145.31
High
180.00
About INSP
Inspire Medical Systems, Inc. is a medical technology company. The Company focuses on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is neurostimulation technology that provides safe and effective treatment for moderate to severe obstructive sleep apnea. The Company's closed-loop solution continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inspire Medical Systems Q1 2026 Earnings Call Insights
- Revenue Growth and Outlook Adjustment: Inspire Medical Systems reported a 1.6% year-over-year revenue increase to $204.6 million in Q1 2026, despite facing approximately $20 million in adverse impacts, leading management to revise the full-year revenue outlook to a range of $825 million to $875 million, reflecting a cautious stance on market conditions.
- Profitability Outlook Decline: The adjusted operating margin is now expected to range from 2% to 4%, with diluted EPS projected between $0.07 and $0.62, indicating challenges in navigating coding and reimbursement uncertainties that may affect future investor confidence.
- Cash Flow and Financial Health: The company generated $12.8 million in operating cash flow for the quarter and maintains a strong balance sheet with $400 million in cash and investments, demonstrating financial flexibility amid a challenging market environment.
- Coding and Reimbursement Challenges: Management highlighted that coding uncertainty has negatively impacted patient numbers, with anticipated adverse effects increasing to $40 million to $50 million in Q2, underscoring the importance of improving reimbursement processes in the coming months.
See More
Inspire (INSP) Q1 2026 Earnings Call Transcript
See More
Inspire Medical Systems Q1 Earnings Exceed Expectations
- Earnings Beat: Inspire Medical Systems reported a Q1 non-GAAP EPS of $0.10, exceeding expectations by $0.36, indicating strong profitability and boosting investor confidence.
- Revenue Growth: The company achieved Q1 revenue of $204.58 million, a 1.6% year-over-year increase, surpassing market expectations by $4.55 million, reflecting stable growth and sustained product demand.
- 2026 Guidance Revision: Inspire revised its 2026 revenue outlook to a range of $825 million to $875 million, representing a decline of 4% to 10% compared to 2025, highlighting challenges in the market environment.
- Profitability Outlook: The company expects an adjusted operating margin of 2% to 4% for 2026, with diluted EPS projected between $0.07 and $0.62, and adjusted diluted EPS ranging from $0.75 to $1.25, indicating a cautious approach to profitability.
See More
Inspire (INSP) Q2 2025 Earnings Call Transcript
See More
Inspire Medical Systems to Announce Q1 Earnings on May 4th
- Earnings Announcement: Inspire Medical Systems is set to release its Q1 2023 earnings on May 4th after market close, with consensus EPS estimate at -$0.26 and revenue at $200.03 million, reflecting a 0.6% year-over-year decline, which could impact investor confidence in the company's future performance.
- Performance Expectations: Over the past year, Inspire has beaten EPS and revenue estimates 100% of the time, although the last three months have seen two upward revisions and seven downward revisions in EPS estimates, indicating market uncertainty regarding the company's profitability.
- Revenue Outlook: Inspire Medical Systems projects 2026 revenue between $950 million and $1 billion, despite facing coding changes and reimbursement challenges, suggesting potential growth opportunities in the OSA implant market as it recovers.
- Market Reaction: Following KeyBanc's prediction that CMS will add codes for the Inspire V implant, Inspire Medical's stock surged, reflecting increased market confidence in the company's future products and potentially driving further development in the medical device sector.
See More
Cash Flow Management and Investment Opportunities Analysis
- Paylocity Investment Risks: Paylocity (NASDAQ:PCTY) has a trailing 12-month free cash flow margin of 23.6%, but its average ARR growth of 13.4% raises concerns as customer hesitance leads to an estimated 7% sales growth for the next 12 months, indicating potential demand slowdown, warranting caution from investors.
- Super Micro Business Growth: Super Micro (NASDAQ:SMCI) achieved an impressive 74.1% annual revenue growth over the past two years, indicating a significant increase in market share, while its earnings per share have outperformed peers with a 45.5% annual growth over the last five years, showcasing its competitive strength in the high-performance server market.
- Inspire Medical Systems Advantages: Inspire Medical Systems (NYSE:INSP) has seen a remarkable 51.2% annual revenue growth over the last five years, with earnings per share compounding at 25.9% annually, and a 19.2 percentage point increase in free cash flow margin, highlighting its market potential in treating obstructive sleep apnea.
- Market Dynamics and Investment Opportunities: While Paylocity's outlook appears bleak, the robust growth of Super Micro and Inspire Medical suggests that investors should focus on these companies' market performance and future potential to seize better investment opportunities.
See More
Inspire Medical Systems Q1 2026 Earnings Call Insights
- Revenue Growth and Outlook Adjustment: Inspire Medical Systems reported a 1.6% year-over-year revenue increase to $204.6 million in Q1 2026, despite facing approximately $20 million in adverse impacts, leading management to revise the full-year revenue outlook to a range of $825 million to $875 million, reflecting a cautious stance on market conditions.
- Profitability Outlook Decline: The adjusted operating margin is now expected to range from 2% to 4%, with diluted EPS projected between $0.07 and $0.62, indicating challenges in navigating coding and reimbursement uncertainties that may affect future investor confidence.
- Cash Flow and Financial Health: The company generated $12.8 million in operating cash flow for the quarter and maintains a strong balance sheet with $400 million in cash and investments, demonstrating financial flexibility amid a challenging market environment.
- Coding and Reimbursement Challenges: Management highlighted that coding uncertainty has negatively impacted patient numbers, with anticipated adverse effects increasing to $40 million to $50 million in Q2, underscoring the importance of improving reimbursement processes in the coming months.
See More
Inspire (INSP) Q1 2026 Earnings Call Transcript
See More
Inspire Medical Systems Q1 Earnings Exceed Expectations
- Earnings Beat: Inspire Medical Systems reported a Q1 non-GAAP EPS of $0.10, exceeding expectations by $0.36, indicating strong profitability and boosting investor confidence.
- Revenue Growth: The company achieved Q1 revenue of $204.58 million, a 1.6% year-over-year increase, surpassing market expectations by $4.55 million, reflecting stable growth and sustained product demand.
- 2026 Guidance Revision: Inspire revised its 2026 revenue outlook to a range of $825 million to $875 million, representing a decline of 4% to 10% compared to 2025, highlighting challenges in the market environment.
- Profitability Outlook: The company expects an adjusted operating margin of 2% to 4% for 2026, with diluted EPS projected between $0.07 and $0.62, and adjusted diluted EPS ranging from $0.75 to $1.25, indicating a cautious approach to profitability.
See More
Inspire (INSP) Q2 2025 Earnings Call Transcript
See More
Inspire Medical Systems to Announce Q1 Earnings on May 4th
- Earnings Announcement: Inspire Medical Systems is set to release its Q1 2023 earnings on May 4th after market close, with consensus EPS estimate at -$0.26 and revenue at $200.03 million, reflecting a 0.6% year-over-year decline, which could impact investor confidence in the company's future performance.
- Performance Expectations: Over the past year, Inspire has beaten EPS and revenue estimates 100% of the time, although the last three months have seen two upward revisions and seven downward revisions in EPS estimates, indicating market uncertainty regarding the company's profitability.
- Revenue Outlook: Inspire Medical Systems projects 2026 revenue between $950 million and $1 billion, despite facing coding changes and reimbursement challenges, suggesting potential growth opportunities in the OSA implant market as it recovers.
- Market Reaction: Following KeyBanc's prediction that CMS will add codes for the Inspire V implant, Inspire Medical's stock surged, reflecting increased market confidence in the company's future products and potentially driving further development in the medical device sector.
See More
Cash Flow Management and Investment Opportunities Analysis
- Paylocity Investment Risks: Paylocity (NASDAQ:PCTY) has a trailing 12-month free cash flow margin of 23.6%, but its average ARR growth of 13.4% raises concerns as customer hesitance leads to an estimated 7% sales growth for the next 12 months, indicating potential demand slowdown, warranting caution from investors.
- Super Micro Business Growth: Super Micro (NASDAQ:SMCI) achieved an impressive 74.1% annual revenue growth over the past two years, indicating a significant increase in market share, while its earnings per share have outperformed peers with a 45.5% annual growth over the last five years, showcasing its competitive strength in the high-performance server market.
- Inspire Medical Systems Advantages: Inspire Medical Systems (NYSE:INSP) has seen a remarkable 51.2% annual revenue growth over the last five years, with earnings per share compounding at 25.9% annually, and a 19.2 percentage point increase in free cash flow margin, highlighting its market potential in treating obstructive sleep apnea.
- Market Dynamics and Investment Opportunities: While Paylocity's outlook appears bleak, the robust growth of Super Micro and Inspire Medical suggests that investors should focus on these companies' market performance and future potential to seize better investment opportunities.
See More
